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Purpose: To describe the features and outcomes of patients with
AIDS-related cytomegalovirus retinitis after highly active antiretroviral
therapy availability. Methods: Retrospective chart review of 30 con-
secutive patients (44 eyes) with AIDS and newly diagnosed, active
AIDS-related cytomegalovirus retinitis, examined from January 2005 to
December 2007. Results: The mean age was 34.8 years, 18 patients
(60.0%) were male and median duration of AIDS was 90 months.
Nineteen patients (63.3%) had evidence of highly active antiretroviral
therapy failure and median CD4+ lymphocyte count was 12.5 cells/µl.
Visual acuity at presentation was 20/40 or better in 27 eyes (61.4%).
Retinitis involved Zone 1 in 13 eyes (39.5%). Despite specific anti-AIDS-
related cytomegalovirus therapy, 16 eyes (36.4%) presented relapse of
retinitis and 10 eyes (22.7%) lost at least three lines of vision. When
compared to highly active antiretroviral therapy responsive patients,
eyes of highly active antiretroviral therapy failure patients were more
likely to develop relapse of retinitis (p=0.03) and loss of at least three
lines of vision (p=0.03). Conclusion: The patients in this series are
essentially young men with longstanding AIDS, non-responsive to
highly active antiretroviral therapy and with a similar immunological
profile as noted before highly active antiretroviral therapy era. These
findings have implications for the management of the disease and confirm
the magnitude of rational periodic screening after diagnosis of AIDS.
ABSTRACT
INTRODUCTION
Since the introduction of highly active antiretroviral therapy (HAART)
in 1996, patients with acquired immunodeficiency syndrome (AIDS) have
been experiencing changes in morbidity and mortality(1-3). The incidence of
systemic complications and opportunistic infections, including cytome-
galovirus (CMV) retinitis declined dramatically compared to the rates from
the pre-HAART era(1-7). Cytomegalovirus retinitis is still one of the most
common ocular manifestations and the major cause of blindness in patients
with AIDS and, despite all the advances in AIDS treatment, it continues to
be diagnosed(4-8).
73(1)13.pmd 24/3/2010, 08:0616
 17Clinical features and outcomes of AIDS-related cytomegalovirus retinitis in the era of highly active antiretroviral therapy
Arq Bras Oftalmol. 2010;73(1):16-21
The estimated lifetime probability of a patient with AIDS
developing CMV retinitis in the pre-HAART era was about
30% (9) but its incidence has declined 55 to 85% after the
introduction of HAART(2-6). In Brazil this drop in the inci-
dence may be explained by the fact that HAART therapy is
distributed with no cost by the National AIDS Programme
from the National Ministry of Health(10). Patients with CD4+
lymphocytes count below 100 cells/µl and especially patients
with CD4+ count 50 cells/µl or less have a proven increased
risk of developing the retinitis(11).
Before HAART, CMV disease was characteristically a re-
lapsing retinitis associated with progressive visual loss despi-
te the repeated specific anti-CMV therapy(7,12). As a conse-
quence of HAART, safe discontinuation of maintenance treat-
ment with anti-CMV medication is possible in patients who
experience immune reconstitution(13-14).
The purpose of this study is to describe the features and
outcomes of Brazilian patients with AIDS-related CMV retini-
tis infected after availability of HAART.
METHODS
From January 2005 to December 2007, active untreated
CMV retinitis was diagnosed in 30 (4.34%) of the 691 con-
secutive patients examined in Uveitis and AIDS Service of the
Federal University of São Paulo - UNIFESP. Medical records,
retinal drawings and fundus photographs were reviewed re-
trospectively. The patients who met the inclusion criteria had
the diagnosis of AIDS according to the 1993 Center for Di-
sease Control and Prevention Revised Surveillance Case De-
finition(15).
Data collection included demographic information, me-
dical and ophthalmic history and a complete ophthalmologic
examination that included pinhole visual acuity measurement
using the Early Treatment Diabetic Retinopathy Study (ETDRS)
chart, external examination, slit-lamp biomicroscopy, intraocu-
lar pressure measurement, and indirect ophthalmoscopy through
a dilated pupil.
The diagnosis of CMV retinitis was based on the clinical
exam and its progression was assessed by the presence of
new lesions or border advancement of existing lesions(16).
Retinitis lesions were described based on size and location.
The location of each lesion was divided into three zones (1, 2
and 3) according to an already established standard classi-
fication system(17).
Patients on HAART therapy were receiving a combination
of antiviral drugs with three or more drugs including at least
one protease inhibitor or non-nucleoside reverse transcriptase
inhibitor. Patients were considered to be HAART-naive if they
were not under this drug regimen.
Newly diagnosed patients had less than 3 months of AIDS
diagnosis. HAART-failure was defined as the presence of
immunologic failure, virologic failure, or both, in patients who
had been receiving HAART for at least 12 weeks before the
diagnosis of CMV retinitis. Immunologic failure was defined
as a CD4+ T lymphocyte count of 50 cells/µl or less. Viro-
logic failure was defined as HIV RNA blood levels of 1,000
copies/ml or more(4). An immunologic response to HAART
was defined as an increase in the CD4+ T cell count by at
least 50 cells/µl from the nadir CD4+ T cell count to a level of
100 cells/µl or more.
Immune recovery uveitis was diagnosed as the presence
of intraocular inflammation in a patient with healed CMV
retinitis who had an immune response to HAART and was
characterized by vitritis, macular edema, or epiretinal membra-
ne formation in association with specific cytokine profiles(18).
Statistical analysis
Statistical analysis was performed using SigmaStat 3.11
(SPSS Inc, Chicago, IL). The distribution of continuous va-
riable is expressed as mean ± standard deviation and catego-
rical data are presented as frequencies. Relationships between
two categorical variables were assessed using Fisher’s exact
test. Student t test was used for analysis of continuous varia-
bles and unpaired t test with Welch correction was used when
applicable.
RESULTS
Thirty patients with newly diagnosed active CMV retinitis
were included. The average age was 34.8 ± 12.6 years (median:
36 years) and 18 patients (60.0%) were male. The most frequent
risk factor for HIV infection was sexual contact with HIV infec-
ted individual (21 patients - 70.0%) and the most frequent risk
factor for CMV disease was HAART-failure (19 patients - 63.3%).
The median duration of AIDS (defined as the time from
diagnosis of AIDS to the first ocular evaluation) was 90 mon-
ths (mean ± SD: 93.2 ± 79.6 months); in two patients (6.7%),
CMV retinitis was an initial manifestation of AIDS. The me-
dian CD4+ lymphocyte count was 12.5 cells/µl (mean ± SD:
26.8 ± 29.9 cells/µl). The median follow-up of the patients was
6.0 months (mean ± SD: 9.0 ± 7.0 months). Demographic and
clinical characteristics are presented in table 1.
Fourteen patients (46.7%) had bilateral disease at the first
visit; one patient with unilateral disease had involvement of
the fellow eye during the follow-up. Most of the patients (24
patients - 80.0%) presented visual symptoms in the first
evaluation and visual blurring was the most frequent (65.9%
of the eyes). The visual acuity at baseline was 20/40 or better
in 27 eyes (61.4%). Anterior segment findings included 1+
anterior chamber cells or more on 7 eyes (15.9%) and fine
keratic precipates on 9 eyes (20.5%). The retinitis involved
Zone 1 in 13 eyes (39.5%) and the area involved was greater
than 50% in 6 eyes (13.6%). Retina was detached in 7 eyes
(15.9%) of 6 patients (20.0%) at the time of the first appoint-
ment, and 7 eyes of 5 patients detached the retina during the
follow-up period. Information regarding ophthalmologic fin-
dings is presented in table 2.
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patients who underwent intravitreal ganciclovir and 24.9 ±
11.7 days in patients that did not require combined local
treatment - p=0.043). No complications such as retinal detach-
ment, cataract or immune recovery uveitis were significantly
associated with this procedure.
Sixteen eyes (36.4%) of nine patients (30.0%) experien-
ced relapse of the retinitis while on maintenance therapy.
The mean duration of the first remission in these patients
was 41.2 ± 42.7 days (median: 22 days). Retinitis relapse was
more likely to occur in eyes of patients with HAART-failure
(p=0.030) and extraocular CMV disease (p=0.002).
Table 2. Ophthalmic characteristics of patients with CMV retinitis
at presentation
Patients* (n=30) Eyes (n=44)
Eye involved
  Right 10 (33.3%) 24 (54.5%)
  Left 6 (20.0%) 20 (45.5%)
  Both 14 (46.7%) NA
Symptoms
  None 6 (20.0%) 10 (12.7%)
  Any symptoms 24 (80.0%) 34 (77.3%)
  Blurring 20 (66.7%) 29 (65.9%)
  Floaters 5 (16.7%) 6 (13.6%)
  Blind spots 7 (23.3%) 10 (22.7%)
Visual acuity
  Categories
    20/15 to 20/20 8 (26.7%) 8 (18.2%)
    20/25 to 20/40 13 (43.3%) 19 (43.2%)
    20/50 to 20/100 5 (16.7%) 7 (15.9%)
    20/200 to 20/400 2 (  6.7%) 2 (  4.5%)
    CF to HM 2 (  6.7%) 4 (  9.1%)
    LPP to NLP 0 (  0.0%) 4 (  9.1%)
Anterior chamber reaction
  None 21 (70.0%) 32 (72.7%)
  0.5+ 4 (13.3%) 5 (11.4%)
  1+ 4 (13.3%) 6 (13.6%)
  2+ 1 (  3.3%) 1 (  2.3%)
Keratic precipitates 7 (23.3%) 9 (20.5%)
Most posterior zone of retinitis
  Zone 1 11 (36.7%) 13 (29.5%)
  Zone 2 11 (36.7%) 17 (38.6%)
  Zone 3 8 (26.7%) 14 (31.8%)
Extent of disease
  ≤ 10% 0 (  0.0%) 3 (  6.8%)
  11% to 24% 17 (56.7%) 24 (54.6%)
  25% to 50% 8 (26.7%) 11 (25.0%)
  >50% 5 (16.7%) 6 (13.6%)
Vitreous cells 7 (23.3%) 8 (18.2%)
Retinal detachment 6 (20.0%) 7 (15.9%)
CMV= cytomegalovirus; CF= counting fingers; HM= hand movement; LLP= light
projection; NLP= no light perception; NA= not applicable
*=
 Percentages based on the presence of finding in either eye (symptoms,
vitreous cells, keratic precipitates and retinal detachment) or worse eye
(anterior chamber reaction, location, extent of disease) for all factors except
visual acuity; for visual acuity, patients were categorized on the basis of vision
in the involved eye or the better eye when disease was bilateral
Table 1. Characteristics of patients with CMV retinitis
Age (mean ± SD), years 34.8 ± 12.6
Male gender 18 (60.0%)
Schooling years
  1-8 15 (50.0%)
  9-11 12 (40.0%)
  ≥ 12 6 (10.0%)
Risk factor for HIV infection
  Sexual contact 21 (70.0%)
  Perinatal exposure 3 (10.0%)
  IV drug use 1 (  3.3%)
  Unknown 5 (16.7%)
Risk factor for CMV disease
  HAART-failure 19 (63.3%)
  Newly diagnosed AIDS 8 (26.7%)
  Poor HAART adherence 3 (10.0%)
  Not in use of HAART 6 (20.0%)
    HAART-naive 2 (  6.7%)
    Past exposure only 4 (13.3%)
Median duration of AIDS (range), months 90 (0 to 240)
Extraocular CMV disease 5 (16.7%)
Median (range) CD4+ T-lymphocyte
count (cells/µl) 12.5 (2 to 102)
HIV viral load (copies/ml) (n=13*)
  400 - 10000 2 (  6.7%)
  >10000 13 (84.6%)
CMV= cytomegalovirus; SD= standard deviation; HIV= human immunodeficiency
virus; IV= intravenous; HAART= highly active antiretroviral therapy; AIDS=
acquired immunodeficiency syndrome
*= number of patients for whom the information was available
Induction and maintenance therapy doses consisted of a
standard regimen(16) with the induction treatment extended
until retinitis healing was achieved, despite the classically 2-3
week course of induction. Twenty-four patients (80.0%) recei-
ved induction therapy with intravenous ganciclovir, two (6.7%)
received intravenous foscarnet regimen and four patients
(13.3%) that started treatment with ganciclovir switched to
foscarnet later on due to inappropriate response or adverse
effects. Ganciclovir was the elected drug for maintenance
therapy in 25 patients (83.3%), foscarnet was elected in 4
(13.3%) and one patient (3.3%) was treated with valganci-
clovir. The average time of induction therapy was 27.8 ± 12.4
days (median: 21 days). Nine patients (12 eyes) underwent
intravitreal injection of ganciclovir (2.0 mg in 0.1 ml - 2.6 ± 1.3
injection per eye). Six patients (21.4%) treated with ganciclovir
experienced myelotoxicity. Patients with HAART-failure re-
quired longer duration of induction therapy when compared
to HAART responsive patients (respectively, 31.3 ± 13.6 and
21.9 ± 7.4 days - p=0.021). Patients with more than 3 month of
AIDS diagnosis also required longer induction treatment than
patients with newly diagnosed AIDS (respectively, 30.3 ± 13.1
and 21.1 ± 7.4 days - p=0.025). Intravitreal injection of gan-
ciclovir was necessary when time of induction therapy was
extended due to lack of response to the systemic treatment
(mean duration of induction therapy was 34.8 ±11.8 days in
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During follow-up, 10 eyes (22.7%) of 8 patients (26.7%) had
at least three lines of visual acuity loss (doubling of the visual
angle) and this was associated with HAART-failure (p=0.031)
and retinal detachment (p=0.006). At the final visit, 15 eyes
(34.1%) were legally blind (20/200 or worse), with a significant
association with zone 1 involvement (p=0.004).
Seven patients (23.3%) presented immune recovery during
follow-up allowing anti-CMV maintenance therapy disconti-
nuation; six of these patients had newly diagnosed AIDS and
only one had more than three months of diagnosis of AIDS. The
mean duration of maintenance therapy was 7.0 ± 4.1 months.
Eight eyes (18.2%) with retinal detachment underwent pars
plana vitrectomy, eight eyes (18.2%) underwent retinal argon
laser photocoagulation and three eyes (6.8%) had phacoemul-
sification with intraocular lens implantation performed. Treat-
ment and clinical outcomes are summarized in table 3.
DISCUSSION
Cytomegalovirus retinitis accounts for 75 to 85% of CMV-
related diseases in AIDS(19-20) and even in the HAART era it
still is the major cause of visual impairment in these pa-
tients(4,8,19-20).
In a previous study from May 2000 to February 2001(1),
4.5% of 200 of our patients were diagnosed with active CMV
retinitis in the first visit. In our series, 5.6% of 691 consecutive
examined patients from January 2005 to February 2007 met the
criteria for newly diagnosed CMV retinitis, suggesting that its
incidence has been stable in the last decade.
New cases of CMV retinitis continue to be diagnosed due
to reasons such as late diagnosis of HIV infection or AIDS,
poor adherence to HAART treatment or viral resistance to one
or more components of HAART therapy(4,21). In developing
countries, CMV retinitis is largely undiagnosed and the scale
of the problem is still not known as there is no strategy for
screening and management of the problem(21).
Patients with CMV retinitis presented a similar immuno-
logical profile as observed in the era before HAART. At that
time patients had low CD4+ T-cell counts and elevated HIV
viral loads(4,12), although patients receiving HAART showed a
broader range of CD4+ count, including values of more than
50 cells/µl(4).
As in other studies, most of these patients have longstan-
ding AIDS, had received HAART and are intolerant or non
responsive to this therapy(4-6). Visual symptoms were frequent
at the time of diagnosis and blurring was the most common
presenting symptom, as previously described(22). Patients with
more severe disease, including HAART-failure and extraocu-
lar CMV disease, had a worse prognosis, evolving with visual
loss and CMV retinitis relapses.
The median time from the diagnosis of AIDS to the first
visit was longer than the median time in previous studies(4,6);
rates of retinal detachment and visual acuity of 20/200 or
worse at presentation were also higher than previously des-
cribed(4,23). This could be explained by the fact that not always
the patients are submitted to a screening performed by an
ophthalmologist that is familiar with the ocular complications
of the disease. These difficulties could be diminished by spe-
cific training programs for general ophthalmologists and the
use of telemedicine for evaluation and second opinion.
Treatment with specific anti-CMV therapy successfully
controlled the disease with minimal complications. In patients
unresponsive to HAART and with long standing AIDS the
duration of induction treatment needed to be prolonged from
the standard 2-3 weeks for adequate control of the retinitis.
Local treatment with intraocular injection of ganciclovir 2.0 mg
was considered an option for patients with inappropriate
response to therapy and play a role in patients with systemic
contraindications to anti-CMV drugs. The procedure was not
associated with complications like retinal detachment or lens
opacification.
Table 3. Treatment characteristics and outcomes of patients with
CMV retinitis
Patients* (n=30) Eyes (n=44)
Induction therapy
  Ganciclovir 24 (80.0%) 36 (81.8%)
  Foscarnet 2 (  6.7%) 3 (  6.8%)
  Ganciclovir and foscarnet 4 (13.3%) 5 (11.4%)
Duration of induction therapy
(mean ± SD, days) 27.8 ± 12.4 27.8 ± 12.4
Ganciclovir intravitreal injection 9 (30.0%) 12 (27.3%)
Maintenance therapy
  Ganciclovir 25 (83.3%) 37 (84.1%)
  Foscarnet 4 (13.3%) 6 (13.6%)
  Valganciclovir 1 (  3.3%) 1 (  2.3%)
Procedures
PPV 7 (23.3%) 8 (18.2%)
Laser photocoagulation 6 (20.0%) 8 (18.2%)
Cataract surgery 2 (  6.7%) 3 (  6.8%)
Final visual acuity
  Categories
  20/15 to 20/20 8 (26.7%) 9 (20.5%)
  20/25 to 20/40 8 (26.7%) 14 (31.8%)
  20/50 to 20/100 6 (20.0%) 6 (13.6%)
  20/200 to 20/400 2 (  6.7%) 3 (  6.8%)
  CF to HM 2 (  6.7%) 3 (  6.8%)
  LPP to NLP 4 (13.3%) 9 (20.5%)
Ocular complications
  Recurrence 9 (30.0%) 16 (36.4%)
  > 3 line loss of visual acuity 8 (26.7%) 10 (22.7%)
  Retinal detachment 11 (36.7%) 14 (31.8%)
  Cataract 4 (13.3%) 6 (13.6%)
  Immune recovery uveitis 3 (10.0%) 3 (  6.8%)
Systemic complication
  Myelotoxicity 6 (20.0%) 9 (20.5%)
CMV= cytomegalovirus; SD= standard deviation; PPV= pars plana vitrectomy;
CF= counting fingers;  HM= hand movement; LLP= light projection; NLP= no light
perception
*=
 Percentages based on the presence of finding in either eye except final visual
acuity; for final visual acuity, patients were categorized on the basis of vision
in the involved eye or the better eye when disease was bilateral
73(1)13.pmd 24/3/2010, 08:0619
20 Clinical features and outcomes of AIDS-related cytomegalovirus retinitis in the era of highly active antiretroviral therapy
Arq Bras Oftalmol. 2010;73(1):16-21
Despite treatment, doubling of the visual angle occurred in
22.7% of the eyes and retinitis recurred in 30% of the patients.
The most common cause of visual loss of 20/200 or worse was
zone 1 involvement(23). Retinal detachment was not signifi-
cantly associated with visual loss of 20/200 or worse in our
series; surgical reattachment of the retina (pars plana vitrec-
tomy with silicone oil tamponade) was successful in the ma-
jority of cases (5 of 8 eyes had visual acuity of 20/40 or better
at the end of the follow-up). The mean duration of first retinitis
remission in eyes with recurrences was shorter than the period
described in the HAART era(5) and similar to the period before
HAART availability(16). Probably the poor immunologic status
of these patients and increasing rates of CMV resistance to
ganciclovir and foscarnet is the reason for this. Unfortunately,
CMV resistance testing was only available for a minority of
patients.
CONCLUSION
This study is retrospective, but the results represent the
heterogeneity of host profiles and clinical features of AIDS-
related CMV retinitis in the HAART era agreeing with the
already published data. These findings have implications for
evaluation and management of disease and confirm the impor-
tance of ophthalmic evaluation after diagnosis of AIDS, ratio-
nal periodic screening of CMV retinitis and prompt treatment.
These strategies are crucial for successful outcomes and pre-
servation of vision.
RESUMO
Objetivo: Descrever as características e evolução clínica de
pacientes com retinite por citomegalovírus relacionada à
AIDS após o advento da terapia antirretroviral potente. Méto-
dos: Estudo retrospectivo dos prontuários de 30 pacientes
consecutivos (44 olhos) com AIDS e retinite por citomega-
lovírus ativa recém-diagnosticada, atendidos entre janeiro de
2005 e dezembro de 2007. Resultados: A idade média dos
pacientes foi de 34,8 anos, 18 pacientes (60,0%) eram do sexo
masculino e a mediana do tempo de diagnóstico de AIDS era
90 meses. Dezenove pacientes (63,3%) apresentavam evidên-
cia de falência da terapia antirretroviral potente e a mediana
da contagem de linfócitos T CD4+ era 12,5 células/µl. A
acuidade visual inicial era melhor ou igual a 20/40 em 27 olhos
(61,4%). A retinite acometia a Zona 1 em 13 olhos (39,5%).
Apesar da terapia antirretinite por citomegalovírus específica,
16 olhos (36,4%) apresentaram recidiva da retinite e 10 olhos
(22,7%) perderam pelo menos três linhas de visão. Quando
comparado aos de pacientes com boa resposta à terapia an-
tirretroviral potente, olhos de pacientes com falência à terapia
antirretroviral potente apresentaram mais recidiva da retinite
(p=0,03) e perda de pelo menos três linhas de visão (p=0,03).
Conclusão: Os pacientes nesta série são essencialmente ho-
mens jovens com longo tempo de diagnóstico de AIDS, má
resposta à terapia antirretroviral potente e com um perfil imu-
nológico semelhante ao encontrado antes do advento da tera-
pia antirretroviral potente. Estes achados têm implicações no
manejo da doença e confirmam a importância da triagem perió-
dica e racional após o diagnóstico de AIDS.
Descritores: Citomegalovírus; Retinite; Síndrome de imuno-
deficiência adquirida; Terapia antirretroviral de alta atividade;
Infecções oportunistas relacionadas com a AIDS; Uveíte pos-
terior; Infecções oculares/etiologia; Infecções por HIV
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